Prognostic factors for survival in patients with metastatic renal cell carcinoma treated with targeted therapies.

ABSTRACT:

Background

The most important prognostic factors for survival in patients with metastatic renal cell carcinoma (mRCC) were evaluated in the era of cytokine therapy, and only recently were revalidating in patients receiving targeted therapies (TTs).

Methods

Clinical data for consecutive patients with mRCC who received TTs were retrieved from the database of Istituto Nazionale dei Tumori of Milan. Variables with a significant association with overall survival (OS) were estimated by proportional hazard regression, and a backward stepwise multivariate analysis identified the independent prognostic factors.

Results

Data for 336 consecutive patients treated with TTs for RCC during the period 2004-2011 were evaluated. According to the Motzer classification, 32% patients were

SUBMITTER: Procopio G 

PROVIDER: S-EPMC3494435 | biostudies-literature | 2012 Oct

REPOSITORIES: biostudies-literature